Skip to content
Clinical Trials – home

Hepatic neoplasm Treatment

In short

Hepatic neoplasms, commonly known as liver tumors, require treatment approaches carefully matched to each patient's specific situation, the stage of the disease, and the overall health of the liver. While some treatments aim to remove or destroy tumors completely, others focus on slowing disease progression or improving quality of life when cure is not possible.

Key points

  • Treatment for hepatic neoplasms must be individualized based on tumor size, location, spread, and liver function—there is no one-size-fits-all approach.
  • The liver's remarkable ability to regenerate allows surgeons to safely remove large portions while leaving enough tissue to sustain life.
  • Immunotherapy has revolutionized treatment for advanced liver cancer, but it doesn't work for everyone and requires careful patient selection.
  • Ablation therapies can destroy tumors without surgery by using heat, cold, or chemicals delivered directly to the cancer.
  • Embolization takes advantage of the liver's unique dual blood supply to starve tumors while preserving healthy tissue.
  • Clinical trials are investigating exciting new approaches including nanoparticle drug delivery, electroporation, and personalized medicine based on tumor genetics.
  • Managing side effects and maintaining quality of life are essential components of comprehensive liver cancer care, not afterthoughts.
  • Early detection through regular screening for high-risk individuals dramatically improves treatment options and outcomes—prevention and surveillance save lives.

Understanding Treatment Goals and Choices

When someone receives a diagnosis of a hepatic neoplasm, the treatment journey begins with understanding what can realistically be achieved. The main goals of treating liver tumors depend heavily on whether the cancer is detected early or has already advanced. For patients with small tumors and relatively healthy liver tissue, the aim is often to remove the cancer completely through surgery or destroy it using specialized techniques. When the disease has spread or the liver is severely damaged from conditions like cirrhosis—which means scarring of the liver from long-term damage—the focus shifts to controlling symptoms, slowing tumor growth, and maintaining the best possible quality of life.

Treatment decisions are never made in isolation. Doctors consider multiple factors including the size and location of the tumor, whether it has spread beyond the liver, the patient's age and general health, and critically, how well the remaining liver is functioning. Because the liver performs over 500 essential functions in the body—from filtering toxins to producing bile for digestion—any treatment must preserve enough healthy liver tissue to sustain life.

Medical societies and expert panels have developed guidelines based on years of research to help doctors choose the most appropriate treatments. These standard approaches have been tested extensively and are known to be effective for specific situations. At the same time, researchers worldwide are investigating new therapies through clinical trials, offering hope that tomorrow's treatments will be even more effective than today's options.

Surgery and Liver Transplantation

Surgery represents the best chance for cure when liver cancer is discovered early. The most common surgical approach is called a partial hepatectomy, where surgeons remove the part of the liver containing the tumor along with a margin of healthy tissue around it. This might mean taking out a wedge of tissue, an entire section of the liver, or even larger portions depending on the tumor's size and location. The remarkable regenerative capacity of the liver allows the remaining tissue to grow back and take over the organ's essential functions.

For some patients, particularly those whose cancer has not spread but whose liver is too damaged by cirrhosis to support partial removal, a liver transplant offers hope. This procedure involves removing the entire diseased liver and replacing it with a healthy organ from a deceased or living donor. Liver transplantation can be life-saving, but the process is complex. Patients must undergo extensive evaluation to ensure they are healthy enough for surgery and that the cancer has not spread beyond the liver. Because donor organs are scarce, waiting periods can be lengthy, during which other treatments may be needed to control the cancer.

Modern surgical techniques have evolved to make procedures less invasive. Some surgeons now perform hepatectomies using laparoscopic or robotic-assisted methods, which involve smaller incisions, potentially leading to faster recovery times and less pain compared to traditional open surgery. However, not every patient is a candidate for these newer approaches.

Ablation Therapies: Destroying Tumors Without Surgery

When surgery is not possible—perhaps because the patient is too ill, the tumor is in a difficult location, or the liver is too damaged—doctors may turn to ablation therapy. These techniques destroy cancer cells without removing them surgically, often through the use of heat, cold, or chemical substances.

Radiofrequency ablation uses special needles inserted directly through the skin or through a small incision in the abdomen to reach the tumor. High-energy radio waves heat these needles and the surrounding tumor tissue, effectively cooking the cancer cells to death. This approach works best for smaller tumors and can sometimes be performed as an outpatient procedure with only local anesthesia.

A similar technique called microwave therapy uses microwaves instead of radio waves to create intense heat within the tumor. The extreme temperatures damage and kill cancer cells or make them more vulnerable to other treatments like radiation or chemotherapy. Cryoablation takes the opposite approach, using an instrument to freeze and destroy cancer cells. Doctors may use ultrasound imaging to guide the freezing probe precisely to the tumor location.

Another ablation method involves injecting pure alcohol, called ethanol, directly into the tumor using a small needle. This percutaneous ethanol injection kills cancer cells on contact. Multiple treatment sessions are usually needed, and the procedure is typically done under local anesthesia, though patients with many tumors might require general anesthesia.

These ablation techniques are generally well-tolerated, though patients may experience temporary pain at the treatment site, fever, or fatigue afterward. The risk of damage to nearby healthy tissue exists but is minimized through careful imaging guidance.

Embolization: Blocking Blood Supply to Tumors

Liver tumors, like all cancers, need oxygen and nutrients from blood to grow. The liver receives blood from two sources: the hepatic portal vein, which supplies healthy liver tissue, and the hepatic artery, which tends to preferentially feed tumors. Embolization therapy takes advantage of this difference by blocking the hepatic artery, essentially starving the tumor while preserving blood flow to healthy liver tissue.

In a procedure called transarterial embolization (TAE), doctors make a small incision in the inner thigh and thread a thin, flexible tube called a catheter up into the hepatic artery. Once positioned correctly, they inject substances that block the artery and stop blood flow to the tumor. A more sophisticated version, transarterial chemoembolization (TACE), combines this approach with chemotherapy. Anticancer drugs are either attached to tiny beads that are injected into the artery or injected as a liquid along with the blocking agent. This delivers chemotherapy directly to the tumor in high concentrations while minimizing exposure to the rest of the body.

These procedures are used for patients who cannot have surgery or ablation and whose cancer has not spread outside the liver. Side effects can include fever, abdominal pain, nausea, and temporary changes in liver function. Most patients recover within a few days to weeks, though multiple treatment sessions may be necessary over time.

Standard Drug Treatments for Advanced Disease

When liver cancer has spread beyond the liver or cannot be treated with local therapies, systemic treatments—medications that travel throughout the body—become the main option. For many years, options were limited, but significant progress has been made in recent decades.

Traditional chemotherapy uses drugs that kill rapidly dividing cancer cells. While chemotherapy is effective for many types of cancer, liver cancer cells have historically been quite resistant to most chemotherapy drugs. However, chemotherapy still plays a role, particularly when delivered directly to the liver through embolization procedures as described above.

Targeted therapy represents a more refined approach, using drugs designed to interfere with specific molecules and pathways that cancer cells need to grow and survive. These medications work differently than traditional chemotherapy and often have different side effects. Several targeted drugs have been approved for treating advanced liver cancer, including medications that block signals telling cancer cells to grow or that prevent tumors from forming new blood vessels to feed themselves.

Common side effects of targeted therapies can include fatigue, diarrhea, high blood pressure, skin problems, and loss of appetite. Doctors monitor patients closely and can adjust doses or prescribe medications to manage these effects. Some foods, like grapefruit and watercress, can interfere with how these drugs work, so patients should follow dietary guidance from their healthcare team.

Treatment duration varies widely depending on how well the cancer responds and how well the patient tolerates the therapy. Some people take these medications for months or even years, with regular check-ups to assess effectiveness and manage side effects.

Radiation Therapy Approaches

Radiation therapy uses high-energy rays or particles to kill cancer cells. While external beam radiation can be used for liver tumors, a specialized approach called selective internal radiation therapy (SIRT) has proven particularly useful. In SIRT, tiny radioactive beads are injected directly into the liver's blood supply. These beads lodge in and around the tumor, delivering radiation directly to cancer cells while sparing most of the healthy liver tissue.

SIRT is typically used for adult patients whose liver has not been too severely damaged and whose cancer cannot be removed surgically. The procedure requires careful planning and is performed by specially trained doctors called interventional radiologists. Side effects can include fatigue, abdominal discomfort, and temporary changes in liver function, but many patients find these manageable.

Innovative Immunotherapy Treatments

One of the most exciting developments in liver cancer treatment is immunotherapy, which harnesses the body's own immune system to recognize and attack cancer cells. The immune system normally patrols the body looking for abnormal cells, but cancer cells have clever ways of hiding from this surveillance. Immunotherapy drugs work by removing these disguises or boosting the immune system's ability to find and destroy cancer.

Checkpoint inhibitors are a type of immunotherapy that has shown particular promise. Cancer cells often exploit certain "checkpoint" molecules that normally prevent the immune system from attacking healthy tissue. By blocking these checkpoints with specialized antibodies, doctors can unleash the immune system against the tumor. Several checkpoint inhibitors have been approved for treating advanced liver cancer, either alone or in combination with other treatments.

The combination of the checkpoint inhibitor atezolizumab with a targeted antibody called bevacizumab has become a standard first-line treatment for certain patients with advanced liver cancer. Atezolizumab targets a checkpoint pathway called PD-L1, while bevacizumab blocks a growth factor called VEGF-A that tumors use to form new blood vessels. Together, these drugs attack the cancer from two directions.

Other approved immunotherapy options include nivolumab and pembrolizumab, which target the PD-1/PD-L1 checkpoint pathway, and durvalumab combined with tremelimumab, which targets multiple checkpoint pathways. Some of these are used after other treatments have stopped working, while others can be first-line options for specific patient groups.

Immunotherapy side effects differ from those of chemotherapy or targeted therapy. Because these drugs activate the immune system, they can sometimes cause the immune system to attack normal tissues, leading to inflammation in various organs. Common issues include fatigue, skin rashes, diarrhea, and hormone problems. More serious side effects affecting the lungs, liver, intestines, or hormone glands can occur but are less common. Doctors monitor patients carefully and can use other medications to manage these immune-related side effects when they arise.

Emerging Therapies in Clinical Trials

While standard treatments continue to improve outcomes, researchers are constantly investigating new approaches through clinical trials. These studies test innovative drugs and treatment strategies to determine if they are safe and more effective than existing options. Participating in a clinical trial can give patients access to cutting-edge therapies before they become widely available, though it's important to understand that experimental treatments may not work and could have unexpected side effects.

Clinical trials typically progress through three phases. Phase I trials focus primarily on safety, determining what dose of a new treatment can be given without causing severe side effects. These studies usually involve small numbers of patients. Phase II trials evaluate whether the treatment actually works against the cancer—does it shrink tumors or help patients live longer? These studies include more patients and provide preliminary evidence of effectiveness. Phase III trials are large studies comparing the new treatment directly against the current standard treatment to see which works better. These trials provide the strongest evidence and are often the final step before a treatment can be approved for widespread use.

Current clinical trials for liver cancer are exploring several promising directions. Researchers are testing new checkpoint inhibitors that target different immune pathways, hoping to help patients whose tumors don't respond to existing immunotherapies. Combinations of different immunotherapy drugs are being studied to see if attacking multiple checkpoints simultaneously produces better results.

Newer targeted therapies are being developed that focus on specific genetic mutations found in liver cancer cells. Scientists have discovered that different liver tumors have different molecular abnormalities driving their growth. By identifying these specific changes through genetic testing of tumor samples, doctors may eventually be able to match each patient with a therapy specifically designed to target their tumor's unique vulnerabilities. This approach, called personalized medicine or precision medicine, is already showing promise in trials.

Nanotechnology represents another frontier in liver cancer treatment. Researchers are developing tiny particles, called nanoparticles, that can carry drugs directly to tumor cells while avoiding healthy tissue. These nanoparticles can be designed to release their payload only when they reach the cancer, maximizing the drug's effect on the tumor while minimizing side effects elsewhere in the body. Some nanoparticle systems use the liver's natural biology to concentrate in liver tumors preferentially.

Novel approaches to ablation therapy are also under investigation. One promising technique called electroporation therapy uses electrical pulses sent through an electrode placed in the tumor to kill cancer cells. Unlike heat-based ablation, electroporation doesn't rely on temperature changes, which may make it safer for tumors near sensitive structures like major blood vessels or bile ducts. This approach is being studied in clinical trials to determine its effectiveness and safety profile.

Researchers are also exploring combination strategies that pair different types of treatment. For example, some trials combine immunotherapy with ablation procedures, based on the theory that destroying tumor cells with heat or cold might release tumor proteins that help the immune system better recognize and attack remaining cancer cells elsewhere in the body. Other studies combine targeted therapies with immunotherapy or traditional treatments.

Clinical trials for liver cancer are conducted at major cancer centers throughout the United States, Europe, and other parts of the world. Eligibility requirements vary depending on the study, but typically include factors like the stage and type of liver cancer, previous treatments received, overall health status, and liver function. Patients interested in clinical trials should discuss options with their oncologist, who can help determine which trials might be appropriate and assist with enrollment if desired.

Surveillance for Early Detection

For very small liver lesions detected during screening—those less than 1 centimeter—a strategy called surveillance is often recommended. This means closely monitoring the lesion with regular exams and imaging tests without immediately starting treatment. Most of these tiny spots turn out to be benign changes related to cirrhosis rather than cancer. Doctors typically recommend follow-up scans every three months using the same imaging technique that first detected the lesion. If the spot grows or changes character, treatment can be initiated promptly.

This watchful waiting approach avoids subjecting patients to the risks and side effects of treatment for something that may not be cancer at all. However, it requires patients to be reliable about attending follow-up appointments and undergoing regular imaging studies. Missing appointments could allow a true cancer to progress undetected.

Most common treatment methods

  • Surgery
    • Partial hepatectomy to remove the part of liver containing the tumor along with surrounding healthy tissue
    • Liver transplant replacing the entire diseased liver with a healthy donor organ
    • Laparoscopic or robotic-assisted procedures using smaller incisions for faster recovery
  • Ablation Therapy
    • Radiofrequency ablation using radio waves to heat and kill cancer cells
    • Microwave therapy creating high temperatures to destroy tumors
    • Cryoablation freezing cancer cells to death
    • Percutaneous ethanol injection delivering pure alcohol directly into tumors
    • Electroporation therapy using electrical pulses to kill cancer cells (in clinical trials)
  • Embolization Therapy
    • Transarterial embolization (TAE) blocking blood flow to tumors
    • Transarterial chemoembolization (TACE) combining blockage with chemotherapy drugs
  • Radiation Therapy
    • Selective internal radiation therapy (SIRT) injecting radioactive beads into liver blood supply
    • External beam radiation targeting tumors from outside the body
  • Immunotherapy
    • Atezolizumab combined with bevacizumab as first-line treatment for advanced liver cancer
    • Nivolumab and pembrolizumab targeting PD-1/PD-L1 checkpoint pathways
    • Durvalumab combined with tremelimumab for unresectable liver cancer
    • Ipilimumab targeting CTLA-4 pathway, used in combination with nivolumab
    • Dostarlimab for cancers with DNA mismatch repair deficiency
  • Targeted Therapy
    • Medications blocking specific molecular pathways cancer cells need to grow
    • Drugs preventing tumors from forming new blood vessels
    • Treatments targeting specific genetic abnormalities in cancer cells
  • Chemotherapy
    • Traditional drugs that kill rapidly dividing cells
    • Often delivered directly to liver through embolization procedures
  • Surveillance
    • Close monitoring of very small lesions under 1 centimeter
    • Regular imaging every three months to watch for changes
    • Treatment initiated if lesions grow or change character

Managing Treatment Side Effects and Quality of Life

All cancer treatments come with potential side effects that can affect daily life. Managing these effects is an essential part of comprehensive cancer care. Many cancer centers have supportive care teams including nurses, nutritionists, social workers, and other specialists who help patients cope with treatment-related challenges.

Fatigue is one of the most common complaints during cancer treatment. This isn't ordinary tiredness—it's an overwhelming exhaustion that doesn't improve with rest. Balancing rest with gentle physical activity often helps. Short walks or light exercise can actually boost energy levels for many people. Eating small, frequent meals provides steady fuel for the body.

Digestive issues including nausea, vomiting, diarrhea, or constipation can make eating difficult. Medications can help control nausea. Eating bland, easily digestible foods in small amounts throughout the day is often better tolerated than large meals. Cold foods may be more appealing than hot foods when nausea is a problem. Staying well hydrated is important, especially if diarrhea is occurring. Patients should inform their healthcare team about persistent digestive problems, as adjustments to treatment or additional medications might help.

Liver cancer and its treatment can cause jaundice, a yellowing of the skin and eyes that occurs when bile cannot drain properly. Jaundice often causes intense itching. Taking lukewarm baths, using mild soaps, applying moisturizers, and wearing loose, soft clothing can provide relief. Medications can help with severe itching. Patients with jaundice should avoid fatty foods since bile helps digest fats, and reduced bile flow makes fat digestion difficult.

Pain management is important for quality of life. Modern pain medicine offers many options, from over-the-counter medications to prescription painkillers to specialized nerve block procedures. Patients should be honest with their healthcare team about pain levels so appropriate treatment can be provided. Complementary approaches like meditation, gentle massage, or heat application may also provide relief.

Maintaining good nutrition can be challenging but is important for strength and healing. A diet rich in vegetables, fruits, whole grains, lean proteins, and low-fat dairy products supports overall health. Small, frequent meals are often easier to manage than three large meals. Patients should discuss any dietary restrictions with their healthcare team, as certain medications or liver conditions may require specific dietary adjustments. Meeting with a registered dietitian can provide personalized nutrition guidance.

The emotional and psychological impact of liver cancer should not be underestimated. Feelings of anxiety, fear, sadness, or anger are completely normal. Many patients find it helpful to talk with a counselor, join a support group, or connect with other patients who understand what they're going through. Family members and caregivers may also benefit from support services, as they often carry significant emotional burdens while supporting their loved one.

Looking Toward the Future

The landscape of liver cancer treatment has changed dramatically over the past decade and continues to evolve rapidly. Where options were once limited, patients now have multiple treatment choices, and new therapies are continuously emerging from research laboratories and clinical trials. The development of immunotherapy has been particularly transformative, offering hope to patients with advanced disease who previously had few options.

Future directions in liver cancer treatment include refining personalized medicine approaches, developing better ways to predict which treatments will work for which patients, improving drug delivery systems to maximize cancer cell killing while minimizing side effects, and combining different types of therapy in synergistic ways. Research into the molecular biology of liver cancer continues to reveal new potential targets for therapy.

Prevention and early detection remain critical. Since most liver cancers develop in people with chronic liver disease from hepatitis, alcohol use, or metabolic conditions, addressing these underlying risk factors can reduce cancer incidence. Hepatitis B vaccination and treatment for hepatitis C, managing alcohol consumption, maintaining healthy weight, and controlling diabetes all contribute to liver health and reduce cancer risk. For those with cirrhosis or chronic liver disease, regular surveillance with imaging and blood tests can detect cancers at earlier, more treatable stages.

Did you know?

  1. The liver can regenerate so effectively that up to 75% of it can be safely removed during surgery, and the remaining portion will grow back to near-normal size within weeks.
  2. Some liver cancer treatments were adapted from techniques originally developed for other diseases—radiofrequency ablation, for example, was first used to treat abnormal heart rhythms before being applied to tumors.
  3. Unlike many other organs, the liver receives blood from two different sources, and doctors exploit this unique biology when performing embolization therapy to starve tumors while preserving healthy tissue.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Where to find support

Patient organisations offering help, community and advocacy

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).